Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 24 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
SPARIVAX from Lennik, company number BE0461323486, closed financial year 2025 with a result of € -6,619 after tax. For that financial year SPARIVAX recorded a gross margin of € -5,372 and equity of € -1,774. Compared with financial year 2024, the result moved from € -4,410 to € -6,619. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.
€ -1,774
▼ € 6,619 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -6,619
▼ 50 % more loss than in 2024
Profit after tax over the fiscal year.
€ 3,478
▼ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -7,971.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 139
▼ 50% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,036
▲ 45% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 730
▲ 15% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 13,738 | € 8,717 | € -3,191 | € -5,372 | ▼ € 2,181 |
| Profit after taxes | € 6,466 | € 1,417 | € -4,410 | € -6,619 | ▼ € 2,209 |
| Equity | € 8,638 | € 9,254 | € 4,845 | € -1,774 | ▼ € 6,619 |
| Total debts | € 31,822 | € 10,336 | € 9,330 | € 14,598 | ▲ 56% |
| Cash | € 8,492 | € 2,439 | € 4,268 | € 3,478 | ▼ 19% |
| Retained profit | € 2,440 | € 3,057 | € -1,353 | € -7,971 | ▼ € 6,619 |
| Dividend | € 800 | € 800 | € 0 | € 0 | |
| Balance sheet total | € 40,459 | € 19,590 | € 14,175 | € 12,824 | ▼ 10% |
Key figures of SPARIVAX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SPARIVAX?
What happened at SPARIVAX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 6,619. Source: NBB ↗
- New establishment in Dilbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 6,466 profit in 2022 to € 6,619 loss in 2025.
Paid € 1,006 in corporate taxes since 2022.
Best year ever: 2022, with € 6,466 profit.
Paid out € 1,600 in dividends to the owners in total.
Management
Behind SPARIVAX is Xavier Draps.
Directors
According to the 2025 annual accounts
Xavier Draps
Director
Establishments
Establishment units
Physical locations of this company
Steenbergstraat 18 B
1750 Lennik
Tuinbouwlaan 3
1700 Dilbeek
Active since 26 September 1997
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0461.323.486
- VAT number
- BE 0461.323.486
- Registered office
- Steenbergstraat 18 B, 1750 Lennik
- Names & denominations
- SPARIVAX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 August 1997
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Handelsbemiddeling in de niet-gespecialiseerde groothandel
Handelsbemiddeling in goederen, algemeen assortiment